One Step Closer to Treating the Global Obesity Epidemic March 22, 2022 - Baystreet.ca NeonMind Biosciences (CSE: NEON) (OTC: NMDBF) is another step closer to treating the global obesity epidemic. At the moment, worldwide obesity has tripled since 1975, says the World Health Organization. Plus, as of 2016, more than 1.9 billion adults were considered overweight, with 650 million considered obese. The good news is psilocybin may be able to help. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight." That could be game-changing news for NeonMind Biosciences and other companies researching the benefits of psychedelics including COMPASS Pathways (NASDAQ:CMPS), Cybin Inc. (NEO:CYBN)(NYSE:CYBN), Field Trip Health Ltd. (TSX:FTRP)(NASDAQ:FTRP), and Mind Medicine Inc. (NASDAQ:MNMD)(NEO:MMED). NEON Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss NeonMind Biosciences, an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today it has filed a new patent application with the United States Patent and Trademark Office related to a novel mechanism of weight loss targeted to specific fat subtypes. The provisional patent application includes data derived from NeonMind’s recent preclinical animal study, incorporating novel findings which indicate, in addition to reiterating weight modulation effects of psilocybin seen in previous studies, the targeted reduction of specific fat subtypes may have beneficial effects on metabolic and cardiovascular health. The filing strengthens NeonMind’s growing IP portfolio and differentiates the commercial profiles of its drug candidates. The company plans to release further details of the study’s findings. If granted, the patent could support NeonMind’s pharmaceutical assets until at least 2042. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind’s additional drug candidate, NEO-002, employs low-dose psilocybin to control appetite. “We are excited by the unique findings from our preclinical studies, which have demonstrated durable therapeutic benefits for weight management in the animal model. Importantly, our novel proprietary findings provide opportunities to develop drugs with highly differentiated target product profiles and broad commercial opportunities,” said Robert Tessarolo, President & CEO of NeonMind. “With the advancement of our research programs and continued expansion of our IP portfolio, NeonMind is positioning itself as a leading innovator in the development of novel psychedelic treatments focused on serving the weight management and obesity market, which has historically been underserved and where a new, effective approach is desperately needed to help people live fuller, healthier lives.” Other related developments from around the markets include: COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD). More than 320 million people globally suffer with major depressive disorder (MDD)i, the leading cause of disability worldwide and one of the fastest growing mental health illnesses. About a third of these patients – 100 million people – aren’t helped by existing therapies and suffer with TRD. Cybin Inc., a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28th - 30th from 9:00 a.m. - 5:00 p.m. ET. Field Trip Health Ltd., a global leader in the development and delivery of psychedelic-assisted psychotherapy, announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health's ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. This end-to-end solution will provide personalized treatment solutions for those seeking to improve their mental health. Mind Medicine, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced that it will host its earnings call on Monday, March 28, 2022, at 8:30 a.m. EDT to discuss its financial results for the full year ended December 31, 2021 and provide a business update. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc. Please click here for full disclaimer. Contact Information: 2818047972 [email protected]
One Step Closer to Treating the Global Obesity Epidemic March 22, 2022 - Baystreet.ca NeonMind Biosciences (CSE: NEON) (OTC: NMDBF) is another step closer to treating the global obesity epidemic. At the moment, worldwide obesity has tripled since 1975, says the World Health Organization. Plus, as of 2016, more than 1.9 billion adults were considered overweight, with 650 million considered obese. The good news is psilocybin may be able to help. That's because psilocybin activates serotonin receptors, or "nature's own appetite suppressant," as noted by Psychology Today. "This powerful brain chemical curbs cravings and shuts off appetite. It makes you feel satisfied even if your stomach is not full. The result is eating less and losing weight." That could be game-changing news for NeonMind Biosciences and other companies researching the benefits of psychedelics including COMPASS Pathways (NASDAQ:CMPS), Cybin Inc. (NEO:CYBN)(NYSE:CYBN), Field Trip Health Ltd. (TSX:FTRP)(NASDAQ:FTRP), and Mind Medicine Inc. (NASDAQ:MNMD)(NEO:MMED). NEON Files New Provisional Patent Application Covering Novel Mechanism of Weight Loss NeonMind Biosciences, an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders, announced today it has filed a new patent application with the United States Patent and Trademark Office related to a novel mechanism of weight loss targeted to specific fat subtypes. The provisional patent application includes data derived from NeonMind’s recent preclinical animal study, incorporating novel findings which indicate, in addition to reiterating weight modulation effects of psilocybin seen in previous studies, the targeted reduction of specific fat subtypes may have beneficial effects on metabolic and cardiovascular health. The filing strengthens NeonMind’s growing IP portfolio and differentiates the commercial profiles of its drug candidates. The company plans to release further details of the study’s findings. If granted, the patent could support NeonMind’s pharmaceutical assets until at least 2042. NeonMind’s lead candidate, NEO-001, aims to produce neuropharmacological changes induced by psilocybin, in conjunction with psychotherapy, to achieve durable weight loss for patients suffering from obesity. NeonMind’s additional drug candidate, NEO-002, employs low-dose psilocybin to control appetite. “We are excited by the unique findings from our preclinical studies, which have demonstrated durable therapeutic benefits for weight management in the animal model. Importantly, our novel proprietary findings provide opportunities to develop drugs with highly differentiated target product profiles and broad commercial opportunities,” said Robert Tessarolo, President & CEO of NeonMind. “With the advancement of our research programs and continued expansion of our IP portfolio, NeonMind is positioning itself as a leading innovator in the development of novel psychedelic treatments focused on serving the weight management and obesity market, which has historically been underserved and where a new, effective approach is desperately needed to help people live fuller, healthier lives.” Other related developments from around the markets include: COMPASS Pathways, a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, and Sermo, a global leader in physician insights, today announced findings from a survey of Sermo physician members that showed two thirds (66%) of doctors surveyed believe psilocybin therapy has potential therapeutic benefit for patients with treatment-resistant depression (TRD). More than 320 million people globally suffer with major depressive disorder (MDD)i, the leading cause of disability worldwide and one of the fastest growing mental health illnesses. About a third of these patients – 100 million people – aren’t helped by existing therapies and suffer with TRD. Cybin Inc., a biopharmaceutical company focused on progressing "Psychedelics to Therapeutics™" is pleased to announce that Doug Drysdale, Cybin’s Chief Executive Officer, will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, taking place March 28th - 30th from 9:00 a.m. - 5:00 p.m. ET. Field Trip Health Ltd., a global leader in the development and delivery of psychedelic-assisted psychotherapy, announced a strategic partnership with Cerebral, the fastest growing online mental health platform. The companies are launching a partnership where Cerebral clinicians can refer qualified clients to Field Trip Health's ketamine assisted therapy, while Field Trip will connect potential clients seeking general psychiatry and teletherapy services to Cerebral. This end-to-end solution will provide personalized treatment solutions for those seeking to improve their mental health. Mind Medicine, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced that it will host its earnings call on Monday, March 28, 2022, at 8:30 a.m. EDT to discuss its financial results for the full year ended December 31, 2021 and provide a business update. Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contains forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. NeonMind Biosciences Inc. has paid three thousand five hundred dollars for advertising and marketing services to be distributed by Winning Media. Winning Media is only compensated for its services in the form of cash-based compensation. Winning Media owns ZERO shares of NeonMind Biosciences Inc. Please click here for full disclaimer. Contact Information: 2818047972 [email protected]